Literature DB >> 28741703

Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.

Manmeet Saluja1, Peter Gilling2.   

Abstract

Intravesical bacillus Calmette-Guérin has been the standard of care for high-risk non-muscle-invasive bladder cancer for 40 years. It remains one of the most successful immunotherapies ever used. Bacillus Calmette-Guérin shows superior efficacy to alternative intravesical treatments, and has an established role in reducing both recurrence and progression in non-muscle-invasive bladder cancer. It remains relatively safe, and has acceptable tolerability of both local and systemic side-effects. The present review provides insights into the role of bacillus Calmette-Guérin compared with alternative treatments both in primary and refractory settings.
© 2017 The Japanese Urological Association.

Entities:  

Keywords:  adjuvant treatment; bacillus Calmette-Guérin; immunotherapy; non-muscle-invasive bladder cancer; urinary bladder neoplasms

Mesh:

Substances:

Year:  2017        PMID: 28741703     DOI: 10.1111/iju.13410

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  13 in total

1.  Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer.

Authors:  Christopher S Garris; Jeffrey L Wong; Jeffrey V Ravetch; David A Knorr
Journal:  Sci Transl Med       Date:  2021-05-19       Impact factor: 17.956

Review 2.  Advances in bladder cancer biology and therapy.

Authors:  Linda Tran; Jin-Fen Xiao; Neeraj Agarwal; Jason E Duex; Dan Theodorescu
Journal:  Nat Rev Cancer       Date:  2020-12-02       Impact factor: 69.800

3.  Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer.

Authors:  Qiao Xiong; Anwei Liu; Qian Ren; Yongping Xue; Xiaowen Yu; Yidie Ying; Hongliang Gao; Haoyuan Tan; Zhensheng Zhang; Wei Li; Shuxiong Zeng; Chuanliang Xu
Journal:  Cell Death Dis       Date:  2020-05-14       Impact factor: 8.469

4.  Renal Tuberculosis Following Intravesical Bacillus Calmette-Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer.

Authors:  Senad Bajramovic; Jasmin Alic; Edna Skopljak; Adisa Chikha; Sanela Vesnic; Velda Smajilbegovic; Damir Aganovic
Journal:  Med Arch       Date:  2020-04

Review 5.  The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses.

Authors:  Alireza Labani-Motlagh; Mehrnoush Ashja-Mahdavi; Angelica Loskog
Journal:  Front Immunol       Date:  2020-05-15       Impact factor: 7.561

6.  Malignant transformation of oral leukoplakia is associated with macrophage polarization.

Authors:  Manuel Weber; Falk Wehrhan; Christoph Baran; Abbas Agaimy; Maike Büttner-Herold; Hatice Öztürk; Kristina Neubauer; Claudia Wickenhauser; Marco Kesting; Jutta Ries
Journal:  J Transl Med       Date:  2020-01-07       Impact factor: 5.531

Review 7.  Inflammatory Response Mechanisms of the Dentine-Pulp Complex and the Periapical Tissues.

Authors:  Kerstin M Galler; Manuel Weber; Yüksel Korkmaz; Matthias Widbiller; Markus Feuerer
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

8.  Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer.

Authors:  Sahyun Pak; Sun-Young Kim; Sung Han Kim; Jae Young Joung; Weon Seo Park; Jinsoo Chung; Kang Hyun Lee; Ho Kyung Seo
Journal:  Front Oncol       Date:  2021-04-02       Impact factor: 6.244

9.  Renal Granulomatosis Post Intravesical Bacillus Calmette-Guerin Therapy for Non-muscle-invasive Bladder Cancer.

Authors:  Karen Tran-Harding; Rashmi T Nair; Halemane Ganesh
Journal:  J Clin Imaging Sci       Date:  2018-04-18

10.  Bladder preservation approach versus radical cystectomy for high-grade non-muscle-invasive bladder cancer: a meta-analysis of cohort studies.

Authors:  Pei-Lin Shen; Ming-En Lin; Ying-Kai Hong; Xue-Jun He
Journal:  World J Surg Oncol       Date:  2018-10-02       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.